Company intelligence / Profile preview
Adjuvance Technologies
Lincoln, Nebraska, United Statesadjuvancetechnologies.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Adjuvance Technologies develops next-generation semi-synthetic and synthetic vaccine adjuvants—primarily the TQL1055 triterpene saponin analog—which show improved immune response and reduced toxicity compared to traditional QS‑21. The company’s focus includes infectious disease vaccines and immuno-oncology applications. As of the most recent updates, their lead candidate TQL1055 was in pre-clinical development with patent protection granted for its composition and use. No published clinical results yet.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Vaccine adjuvants (notably saponin-based)Vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Adjuvance Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adjuvance Technologies.